Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten Boers

Showing results (181-190 of 308) with videos related to

Pageof 31
Sort By:
Annals of the Rheumatic Diseases|August 22, 2023
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trialsWalter P Maksymowych, Robert Landewe, Maarten Boers, et al.
Arthritis Care & Research|July 28, 2015
Effective Treatment for Rapid Improvement of Both Disease Activity and Self-Reported Physical Activity in Early Rheumatoid ArthritisNicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, et al.
Arthritis Care & Research|October 4, 2016
Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?Nicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, et al.
RMD Open|November 10, 2017
Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trialMarieke M Ter Wee, Veerle Mh Coupé, Debby den Uyl, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
RMD Open|March 9, 2021
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trialLaurette van Boheemen, Samina Turk, Marian van Beers-Tas, et al.
Plos One|July 28, 2015
Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic PainMartine H P Crins, Leo D Roorda, Niels Smits, et al.
Annals of the Rheumatic Diseases|November 22, 2015
Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE studyMaria-Antonietta D'Agostino, Richard J Wakefield, Hilde Berner-Hammer, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 3, 2025
Systematic reviews of patient-reported outcome measures (PROMs): table templates for effective communicationEllen B M Elsman, Maarten Boers, Caroline B Terwee, et al.
Pageof 31

Showing results (181-190 of 308) with videos related to

Sort By:
Pageof 31
Annals of the Rheumatic Diseases|August 22, 2023
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, et al.
The Journal of Rheumatology|March 9, 2007
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trialsWalter P Maksymowych, Robert Landewe, Maarten Boers, et al.
Arthritis Care & Research|July 28, 2015
Effective Treatment for Rapid Improvement of Both Disease Activity and Self-Reported Physical Activity in Early Rheumatoid ArthritisNicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, et al.
Arthritis Care & Research|October 4, 2016
Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?Nicole P C Konijn, Lilian H D van Tuyl, Maarten Boers, et al.
RMD Open|November 10, 2017
Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trialMarieke M Ter Wee, Veerle Mh Coupé, Debby den Uyl, et al.
Seminars in Arthritis and Rheumatism|October 23, 2016
Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSimon Tarp, Daniel E Furst, Anna Dossing, et al.
RMD Open|March 9, 2021
Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trialLaurette van Boheemen, Samina Turk, Marian van Beers-Tas, et al.
Plos One|July 28, 2015
Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic PainMartine H P Crins, Leo D Roorda, Niels Smits, et al.
Annals of the Rheumatic Diseases|November 22, 2015
Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE studyMaria-Antonietta D'Agostino, Richard J Wakefield, Hilde Berner-Hammer, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 3, 2025
Systematic reviews of patient-reported outcome measures (PROMs): table templates for effective communicationEllen B M Elsman, Maarten Boers, Caroline B Terwee, et al.
Pageof 31